RNF135-Related Overgrowth Syndrome

RNF135-related overgrowth syndrome is a very rare genetic condition. It happens when there is a change (variant) or a small missing piece (deletion) in a gene called RNF135 on chromosome 17 (region 17q11.2). This gene helps control how cells grow and how the body responds to infection. When one copy of this gene does not work properly, the child can grow faster and larger than usual and may have learning and developmental problems.

RNF135-related overgrowth syndrome is a very rare genetic condition in which a change (pathogenic variant) in the RNF135 gene causes tall stature, a large head (macrocephaly), learning or developmental difficulties, and typical facial features. Only a small number of patients have been described worldwide, so most knowledge comes from single case reports and small series.

The RNF135 gene sits near the NF1 gene on chromosome 17 and encodes a RING-finger E3 ubiquitin ligase that helps control cell growth and antiviral immune signaling. When one copy of the gene does not work properly (haploinsufficiency), growth signals during development can become unbalanced, leading to generalized overgrowth and neurological problems.

The syndrome was first described in families with children who had tall height, large body size (macrosomia), large head size (macrocephaly), and a special pattern of facial features, plus learning difficulties. This group of findings was called “macrocephaly, macrosomia, and facial dysmorphism syndrome (MMFD)”, and later linked to variants or deletions involving RNF135.

In many people, RNF135-related overgrowth happens because of a larger deletion that also removes the NF1 gene and nearby genes in the same region. This is sometimes called chromosome 17q11.2 deletion syndrome or NF1 microdeletion syndrome. In these cases, features of both neurofibromatosis type 1 and overgrowth are seen together.

More recently, large population studies have suggested that some RNF135 variants may not always cause a clear disease on their own, and that the condition may be part of a broader 17q11.2 deletion spectrum. This means doctors now interpret RNF135 changes very carefully and usually confirm the diagnosis using both clinical signs and detailed genetic testing.

---

Another names

RNF135-related overgrowth syndrome is known by several other names in medical databases and articles. These names all describe very similar or overlapping conditions and are often used for the same group of patients.

Other names (synonyms)

• Macrocephaly, macrosomia, and facial dysmorphism syndrome (MMFD) – highlights the large head, large body size, and distinctive facial appearance that are typical.

• Overgrowth–macrocephaly–facial dysmorphism syndrome – another way to describe the same pattern of body overgrowth, head enlargement, and facial differences.

• Chromosome 17q11.2 deletion syndrome, 1.4 Mb – name used when a standard 1.4-megabase microdeletion at 17q11.2 includes RNF135, NF1, and several nearby genes.

• NF1 microdeletion syndrome / neurofibromatosis type 1 microdeletion syndrome – names used when NF1 and neighboring genes, including RNF135, are deleted, causing both NF1 features and overgrowth.

• Van Asperen syndrome – historical name used for patients with NF1 microdeletions and overgrowth, later shown to involve the same chromosomal region including RNF135.

• Chromosome 17q11.2 deletion syndrome or monosomy 17q11 – broader chromosomal terms used when a segment of the long arm of chromosome 17 that includes RNF135 is missing.

Types 

• Isolated RNF135 intragenic variant or deletion – the change affects mainly the RNF135 gene itself, without removing the whole NF1 region. Reported patients had tall stature, macrocephaly, facial dysmorphism, and developmental delay, sometimes with autism traits or epilepsy.

• Classic 17q11.2 microdeletion with NF1 and RNF135 – the common 1.4 Mb NF1 microdeletion removes NF1 and RNF135 together. These patients often have NF1 skin signs, a large number of neurofibromas, increased tumor risk, plus overgrowth and learning problems.

• Atypical 17q11.2 deletions including RNF135 – in some people, different-sized deletions include RNF135 and various neighboring genes. The exact features may vary depending on which genes are lost, but overgrowth and facial dysmorphism are common themes.

• Familial versus apparently de novo cases – in several families, RNF135 variants or deletions are inherited in an autosomal dominant pattern, with parents and siblings showing similar but sometimes milder features. In some others the change seems to appear for the first time in the child.

---

Causes

In simple words, the main cause of RNF135-related overgrowth syndrome is a genetic change that reduces the working amount of the RNF135 gene. Below are 20 detailed points that explain this and related factors.

1. Loss-of-function mutation in RNF135
   A loss-of-function mutation is a spelling change in the DNA that stops the RNF135 protein being made properly, often by creating a “stop” signal too early (nonsense) or shifting the reading frame (frameshift). Having only one working copy (haploinsufficiency) is thought to lead to overgrowth and learning problems in some families.

2. Missense variants that change RNF135 protein structure
   Some people carry missense variants, where just one amino acid in the RNF135 protein is changed. A few of these have been reported more often in people with autism and developmental differences, suggesting they may subtly disturb protein function, although their exact disease-causing role is still under study.

3. Intragenic deletion of RNF135
   In some patients, a small deletion removes part or all of the RNF135 gene itself. This intragenic deletion leaves neighboring genes intact but still halves the gene dose, which has been linked to tall stature, dysmorphic features, and developmental delay.

4. Classic 17q11.2 microdeletion including NF1 and RNF135
   The common 1.4 Mb microdeletion at 17q11.2 removes a block of genes, including NF1 and RNF135. Children with this deletion often have a severe form of NF1 plus overgrowth and learning difficulties, suggesting that loss of RNF135 contributes to the growth features.

5. Atypical 17q11.2 deletions that include RNF135
   Some people have differently sized deletions in the 17q11.2 region. When RNF135 is within the missing segment, overgrowth and macrocephaly may appear even if the exact boundaries of the deletion are unusual.

6. Autosomal dominant inheritance from an affected parent
   In several families, the RNF135 change is passed from parent to child in an autosomal dominant way. This means having a single altered copy can be enough to show features, although the severity can differ between family members.

7. De novo mutation in egg or sperm cells
   Sometimes the RNF135 variant or deletion is not found in either parent and appears for the first time in the child. This kind of new (de novo) change likely happens by chance during the formation of egg or sperm cells or very early after conception.

8. Possible parental germline mosaicism
   In rare cases, a parent might have the RNF135 change in some of their egg or sperm cells but not in their blood. This is called germline mosaicism and can explain why more than one child is affected even if standard parental testing looks normal. It is a general mechanism seen in many genetic syndromes.

9. Disruption of RNF135 regulatory regions
   Some structural changes in chromosome 17 may not remove the RNF135 coding region but may disturb nearby control elements that switch the gene on and off. This can reduce RNF135 expression and mimic the effect of a direct gene deletion.

10. RNF135 haploinsufficiency and growth signaling
    RNF135 is an E3 ubiquitin ligase that participates in signaling pathways inside cells. When only one copy is working, growth signals and brain development signals may be slightly unbalanced, leading to tall stature, large head, and neurodevelopmental issues.

11. Combined loss of RNF135 and other flanking genes
    Studies in NF1 microdeletion patients suggest that losing both RNF135 and other nearby genes, such as ADAP2, may together increase the risk of malignant tumors and modify the overgrowth pattern, showing that gene–gene interactions are important.

12. Variation in other growth-related genes
    Some people with RNF135 changes may also carry variants in other growth pathway genes. These background genetic factors can make overgrowth and facial changes more or less obvious and may partly explain why the same RNF135 change looks different between families.

13. Coexisting NF1 gene loss
    When the NF1 gene is also deleted, features of neurofibromatosis type 1, such as café-au-lait spots and neurofibromas, are added to the picture. These extra features come mainly from NF1 loss, but the same deletion also removes RNF135 and likely adds to the overgrowth.

14. Reduced penetrance of some RNF135 variants
    Large population studies have shown that not every person with a rare RNF135 variant has a clear syndrome. This suggests that some variants have low penetrance, meaning they increase risk but do not always cause obvious disease.

15. Epigenetic effects on the 17q11.2 region
    Epigenetic changes, such as abnormal DNA methylation around the 17q11.2 region, may change how much RNF135 and neighboring genes are expressed. These epigenetic effects may interact with deletions or variants and influence how strongly the syndrome appears.

16. Microdeletion formed by non-allelic homologous recombination
    The classic 17q11.2 microdeletion often arises when similar DNA sequences mis-align during cell division. This mechanism, called non-allelic homologous recombination, can delete the segment containing RNF135 and NF1 in a single event.

17. Parental low-level mosaic 17q11.2 deletion
    Occasionally, a parent may carry the 17q11.2 deletion in only a portion of their cells and show mild or no features, but can still pass the full deletion, including RNF135 loss, to a child who then has a more typical overgrowth phenotype.

18. Dosage imbalance from complex rearrangements
    Some structural chromosome changes (like complex rearrangements or duplications with nearby deletions) may change the dosage of RNF135. While overgrowth is mainly linked to loss, unusual dosage patterns may further modify growth and neurodevelopment.

19. Variants of uncertain significance (VUS) in RNF135
    Clinical databases list many RNF135 variants that are still classified as “uncertain significance”. These are changes whose effects are not yet clear; some may later be shown to contribute to overgrowth when combined with other factors.

20. Contiguous gene deletion disorder involving RNF135
    Because the typical deletion removes several genes at once, RNF135-related overgrowth is best understood as part of a contiguous gene deletion syndrome. Loss of RNF135 seems to play a major role in the overgrowth and facial features, while loss of other genes adds extra signs like tumor risk.

---

Symptoms

1. General body overgrowth (tall stature and macrosomia)
   Many children are noticeably tall and large for their age. Their height and weight often lie above the 97th centile lines on growth charts. This generalized body overgrowth is one of the core features that led doctors to group these patients into an overgrowth syndrome.

2. Large head size (macrocephaly)
   Head circumference is often larger than expected for age and sex. The head may look broad or long, and it can stand out even when body size is also big. Macrocephaly is specifically mentioned in clinical summaries of the 17q11.2 deletion / RNF135-related overgrowth group.

3. Distinctive facial appearance (facial dysmorphism)
   Children may share a pattern of facial features, such as a broad or high forehead, wide-spaced eyes, downslanted eye openings, a thick lower lip, and a relatively thin upper lip. These facial signs help geneticists recognize the syndrome at the bedside.

4. Developmental delay (motor and speech)
   Many affected children sit, walk, or talk later than their peers. They may need extra support with fine motor skills, such as writing or using cutlery, and often benefit from early physical, occupational, and speech therapy.

5. Learning difficulties or intellectual disability
   School-age children may struggle with understanding, memory, or problem-solving tasks. Difficulties range from mild learning problems to more significant intellectual disability, and many will need special educational support or individualized teaching plans.

6. Autism spectrum traits and social communication issues
   Some people with RNF135 variants or deletions show autism-like features, such as difficulty with social interaction, restricted interests, or repetitive behaviors. RNF135 is listed as a syndromic autism gene candidate, indicating a link between gene changes and autistic features in part of this group.

7. Low muscle tone and joint laxity
   Hypotonia (low muscle tone) and increased joint looseness can cause a floppy or flexible appearance, delayed walking, and clumsiness. Some children with 17q11.2 deletions have increased joint laxity and postural problems that fit with this pattern.

8. Spine and skeletal changes
   Skeletal issues such as scoliosis (curved spine), pectus excavatum (sunken chest), or bone cysts have been reported in some patients. Regular orthopedic review may be needed when these changes are present, especially in growing children.

9. Skin signs of neurofibromatosis (in NF1-deletion cases)
   When NF1 is also deleted, children usually have café-au-lait spots, freckling in the armpits or groin, and a tendency to develop multiple neurofibromas (nerve-sheath tumors) over time. These skin signs are part of NF1 but often appear together with RNF135-related overgrowth when the deletion includes both genes.

10. Eye problems
    Eye findings can include Lisch nodules (small harmless bumps on the iris in NF1) and other eye abnormalities such as squint (strabismus) or refractive errors. Regular eye examinations help protect vision, especially in children with NF1 microdeletion plus RNF135 loss.

11. Hearing loss
    Some reports describe hearing problems in patients with RNF135 mutations or deletions. Hearing loss may be conductive or sensorineural and can affect speech and learning if not picked up early, so hearing checks are important.

12. Congenital heart defects
    A proportion of children with 17q11.2 deletions have structural heart problems, such as holes in the heart walls or valve defects. These may cause breathlessness, poor feeding in infants, or may be picked up on screening echocardiograms.

13. Seizures or epilepsy
    Epileptic seizures have been described in patients with RNF135 intragenic deletions and overgrowth. Seizures may range from brief staring episodes to more obvious convulsions and usually require neurological evaluation and EEG testing.

14. Endocrine findings such as precocious puberty
    A published case described a girl with RNF135 intragenic deletion who developed early puberty, cystic ovaries, and focal epilepsy. This shows that endocrine features like peripheral precocious puberty can sometimes be part of the extended clinical picture.

15. Behavioral and emotional difficulties
    Children may have anxiety, attention problems, or other behavioral challenges related to their developmental profile and learning difficulties. These issues are not specific to RNF135 but are often seen in overgrowth and neurodevelopmental syndromes.

---

Diagnostic tests

Doctors use a mix of clinical assessment and laboratory / imaging tests to diagnose RNF135-related overgrowth syndrome and to rule out other causes of overgrowth.

Physical examination (bedside clinical exam)

1. Growth measurements
   Height, weight, and head circumference are plotted on standard growth charts. Persistent measurements well above the average, especially with a large head, suggest an overgrowth syndrome and guide further testing.

2. Dysmorphology assessment
   A clinical geneticist carefully examines facial features, head shape, limbs, hands, and feet. Recognizing patterns like macrocephaly, wide-spaced eyes, and thick lower lip can point toward RNF135-related or 17q11.2 deletion syndromes.

3. Skin examination
   The skin is checked for café-au-lait spots, freckling, and neurofibromas. Finding many such signs suggests NF1 microdeletion, which often includes RNF135 and strengthens the suspicion of a contiguous gene deletion syndrome.

4. Neurological examination
   Doctors assess muscle tone, reflexes, coordination, and gait. Low tone, poor coordination, or abnormal reflexes support the presence of an underlying neurodevelopmental or genetic syndrome.

5. Developmental and behavioral assessment
   Standard tools and questionnaires are used to check speech, motor skills, learning level, and social behavior. These structured assessments help document developmental delay, intellectual disability, or autism traits.

Manual / bedside functional tests

6. Motor function tests (fine and gross motor)
   Simple bedside tasks, such as walking on tiptoe, balancing on one leg, drawing shapes, or stacking blocks, help gauge muscle tone and coordination. Difficulty with these tasks can support the clinical suspicion of a syndromic overgrowth condition.

7. Vision screening tests
   Reading from vision charts or using age-appropriate picture charts checks for reduced eyesight or strabismus. Vision problems are common in NF1 microdeletion syndromes and need early detection.

8. Basic hearing screening
   Bedside hearing checks or simple audiometry screen for hearing loss. Because hearing problems have been noted in some RNF135-related cases, early screening can improve language outcomes.

Laboratory and pathological tests

9. Chromosomal microarray (CMA)
   CMA looks for small gains or losses of DNA across all chromosomes. It is a key test to detect the 17q11.2 microdeletion that includes NF1 and RNF135 and is widely recommended in children with unexplained overgrowth and developmental delay.

10. MLPA or targeted deletion/duplication analysis
    Multiplex ligation-dependent probe amplification (MLPA) or similar methods can specifically test for deletions or duplications in NF1 and RNF135. This is useful if a microarray is normal but clinical suspicion of a regional deletion remains high.

11. RNF135 gene sequencing
    Sequencing the RNF135 gene checks for point mutations or small insertions/deletions. This test is often included as part of a broader gene panel for overgrowth or intellectual disability and was how RNF135 loss-of-function variants were first identified.

12. Multigene panel for overgrowth and developmental disorders
    Targeted panels examine many overgrowth and neurodevelopment genes at once, including NSD1, EZH2, DNMT3A, and RNF135. This approach helps distinguish RNF135-related overgrowth from other similar syndromes like Sotos or Weaver syndromes.

13. Whole exome or whole genome sequencing
    If panel testing is negative or unclear, exome or genome sequencing can look more widely for rare variants. These methods were used in large population studies to re-evaluate the disease role and penetrance of RNF135 variants.

14. Baseline blood tests (general health check)
    Tests such as full blood count, liver and kidney function, and basic metabolic panels do not diagnose RNF135-related overgrowth directly, but they help rule out other causes of overgrowth and monitor general health in affected children.

15. Hormone and puberty labs
    When early puberty is suspected, doctors may measure hormones such as LH, FSH, estradiol, and testosterone. Abnormal levels, especially together with ovarian cysts, have been reported in a girl with RNF135 intragenic deletion and precocious puberty.

Electrodiagnostic tests

16. Electroencephalogram (EEG)
    EEG records brain electrical activity and is used when seizures or episodes of staring or unresponsiveness occur. In RNF135-related cases with epilepsy, EEG helps classify the seizure type and guide treatment.

17. Nerve conduction studies and EMG (in selected cases)
    If there are signs of nerve involvement, especially in NF1 microdeletion patients with many neurofibromas, nerve conduction studies or EMG can check how well nerves and muscles work. These tests are not routine but can be useful in complex cases.

Imaging tests

18. Brain MRI
    Magnetic resonance imaging of the brain can look for structural differences, signs of macrocephaly, and NF1-related tumors if NF1 is also deleted. It is especially helpful when seizures, developmental delay, or abnormal head growth are present.

19. Spine and skeletal imaging (X-ray or MRI)
    X-rays or MRI of the spine may be done if scoliosis or bone pain is present. These images help detect bone cysts, curvature, or other skeletal problems reported in some 17q11.2 deletion / RNF135-related cases.

20. Echocardiogram and abdominal / pelvic ultrasound
    An echocardiogram checks the heart for structural defects that can occur in this deletion spectrum. Abdominal or pelvic ultrasound may be done to look for organ anomalies or, in girls with early puberty, to detect ovarian cysts, as described in the expanded RNF135 phenotype case.

Non-pharmacological treatments

1. Early developmental stimulation programs
Early intervention services focus on stimulating movement, language, and social skills from infancy. Therapists use play-based activities to encourage rolling, sitting, crawling, and early communication. The purpose is to strengthen brain pathways while they are still very plastic. Mechanistically, repeated sensory and motor experiences help shape synaptic connections, which can partly compensate for developmental delays caused by RNF135-related brain changes.

2. Physiotherapy for motor skills and tone
Physiotherapists design exercises to improve balance, coordination, muscle strength, and joint flexibility. Sessions may include stretching, gait training, and balance work with step blocks or soft mats. The purpose is to prevent contractures, reduce falls, and support age-appropriate mobility. Mechanistically, targeted repetitive movement increases muscle strength and optimizes motor cortex pathways, helping the child use their body more efficiently despite underlying brain or skeletal differences.

3. Occupational therapy for daily living
Occupational therapists teach children how to manage everyday tasks such as feeding, dressing, writing, and using assistive tools. The purpose is to maximize independence at home and school. Mechanistically, OT breaks complex actions into smaller steps and uses repetition plus environmental adaptations (special grips, adaptive cutlery, seating supports) to bypass fine-motor and planning difficulties that often accompany developmental disorders.

4. Speech and language therapy
Many children with RNF135-related overgrowth syndrome have delayed speech or language processing. Speech therapists use picture cards, play, and structured exercises to improve vocabulary, articulation, and understanding. The purpose is to support communication and social participation. Mechanistically, frequent practice strengthens auditory-language circuits and supports alternative communication methods (signs, communication boards) if spoken language is slow to develop.

5. Special education support and individualized education plans (IEPs)
School-based special education services provide extra classroom support, modified tasks, visual schedules, and reduced distractions. The purpose is to match learning demands to the child’s developmental level. Mechanistically, structured teaching, repetition, and multi-sensory materials help children with cognitive or attention difficulties encode and retrieve information more effectively.

6. Behavioral therapy and parent training
If there are behavior issues, anxiety, or attention problems, psychologists can use behavioral therapy and parent-training programs. The purpose is to reduce challenging behaviors and improve emotional regulation. Mechanistically, these programs rely on learning theory: consistent positive reinforcement builds desired behaviors, while predictable consequences reduce unsafe or disruptive actions.

7. Cognitive-behavioral therapy (CBT) for older children and teens
For older patients who can reflect on thoughts and feelings, CBT helps manage anxiety, low mood, or social worries linked to visible overgrowth or learning issues. The purpose is to teach coping skills, challenge negative thoughts, and improve self-esteem. Mechanistically, CBT reshapes thinking patterns and behavioral responses, which can reduce stress hormones and improve daily functioning.

8. Genetic counseling for families
Genetic counselors explain what RNF135-related overgrowth syndrome is, how it is inherited, and what the recurrence risks are for future pregnancies. The purpose is to support informed family planning and reduce guilt or confusion. Mechanistically, better understanding reduces uncertainty and helps families coordinate appropriate testing of relatives and siblings where indicated.

9. Regular growth and orthopedic monitoring
Because overgrowth can lead to joint strain, limb length differences, or scoliosis, regular review by orthopedic specialists is essential. The purpose is early detection of spine curvature, hip problems, or foot deformities. Mechanistically, timely bracing, physiotherapy, or shoe inserts can direct growth forces more evenly, lowering the need for major surgery later.

10. Neurology follow-up for seizures or abnormal EEG
Some reported patients have epilepsy or focal brain abnormalities. Pediatric neurologists monitor for seizures, adjust medications, and arrange EEG and MRI scans. The purpose is seizure control and prevention of further brain injury. Mechanistically, early recognition and treatment of seizures reduce repeated abnormal electrical activity that can further impair development.

11. Pediatric cardiology monitoring
RNF135 variants may coexist with congenital heart disease in some patients. Regular echocardiograms and ECGs check heart structure and rhythm. The purpose is to detect defects or arrhythmias early. Mechanistically, timely diagnosis allows medicines or surgery to correct abnormal blood flow and prevent chronic strain on the heart and lungs.

12. Pediatric endocrinology and puberty management
Case reports describe precocious puberty and ovarian cysts in RNF135-related overgrowth. Pediatric endocrinologists monitor growth velocity, bone age, and hormone levels. The purpose is to manage overly rapid growth and puberty timing. Mechanistically, hormonal therapies can slow down early puberty, protecting final adult height and reducing psychosocial stress.

13. Nutritional assessment and healthy-weight counseling
Children who are tall and large can still be under- or over-nourished. A dietitian reviews calorie, protein, and micronutrient intake. The purpose is to support optimal growth without excess weight, which worsens joint problems. Mechanistically, balanced nutrition supports bone mineralization, muscle strength, and brain development while limiting metabolic strain.

14. Orthotic devices and adaptive equipment
Custom foot orthotics, ankle-foot orthoses, specialized seating, and mobility aids (walkers, wheelchairs) may be used when needed. The purpose is to improve posture, reduce fatigue, and prevent falls. Mechanistically, external supports redistribute forces across joints and help compensate for muscle imbalance or abnormal bone alignment.

15. Vision and hearing support
Regular eye and ear checks are important because subtle sensory problems can further delay development. The purpose is early correction of refractive errors or hearing loss with glasses or hearing aids. Mechanistically, improving sensory input enhances language learning, balance, and classroom participation.

16. Social work and financial support services
Social workers help families access disability benefits, respite care, and community resources. The purpose is to reduce caregiver stress and financial burden. Mechanistically, better social support lowers chronic stress hormones (like cortisol) in both child and caregivers, improving overall family functioning.

17. Psychological support for parents and siblings
A chronic, rare disorder affects the entire family. Counseling for parents and siblings offers a safe space to process grief, guilt, or worry. The purpose is to reduce burnout and improve family resilience. Mechanistically, emotional support and problem-solving strategies buffer the impact of long-term caregiving stress.

18. Community and peer-support groups
Connecting with other families facing overgrowth or rare genetic syndromes can reduce isolation. The purpose is to share practical tips and emotional support. Mechanistically, peer support lowers perceived stress and can improve adherence to complex care plans by exchanging strategies that work in everyday life.

19. Sleep hygiene and behavioral sleep programs
Sleep problems are common in children with neurodevelopmental conditions. Structured bedtime routines, minimizing screens before bed, and behavioral sleep strategies can be used. The purpose is to improve sleep quality, which supports learning and mood. Mechanistically, adequate sleep stabilizes neurotransmitter levels and enhances memory consolidation.

20. Transition planning to adult services
As the child grows, a structured transition to adult neurologists, endocrinologists, and primary care is needed. The purpose is to maintain continuity of care and encourage self-management skills. Mechanistically, early planning reduces gaps in monitoring, helping prevent untreated complications during adolescence and adulthood.

---

Drug treatments

There is no drug that specifically corrects the RNF135 gene. The medicines below are examples of standard drugs used to treat common associated problems such as seizures, ADHD, mood or behavior disorders, and endocrine issues. All are prescription-only and must be dosed and monitored by specialists.

1. Levetiracetam (Keppra) – anti-seizure drug
Levetiracetam is a broad-spectrum antiepileptic used to treat focal and generalized seizures in children and adults. It is often chosen for developmental disorders because it has relatively few drug interactions. The medicine is taken by mouth or intravenously in divided daily doses. Its purpose is to stabilize brain electrical activity and reduce seizure frequency. Mechanistically, it binds to synaptic vesicle protein SV2A, modulating neurotransmitter release. Side effects can include drowsiness, irritability, mood changes, and, rarely, serious allergic reactions.

2. Valproate (valproic acid / divalproex) – anti-seizure and mood stabilizer
Valproate is another antiepileptic used for generalized and focal seizures and sometimes for mood stabilization. It is usually given in two or more divided doses daily. Its purpose is to control seizures that may arise from cortical malformations or other brain abnormalities. Mechanistically, it increases GABA levels and modulates sodium and calcium channels. Side effects include weight gain, tremor, liver toxicity, and teratogenicity, so monitoring of liver function and blood counts is essential.

3. Lamotrigine – anti-seizure and mood stabilizer
Lamotrigine is used in focal and generalized epilepsies and bipolar disorder. For children with developmental syndromes, it may help when seizures and mood problems coexist. It is started at a very low dose and increased slowly to reduce the risk of rash. Mechanistically, lamotrigine blocks voltage-sensitive sodium channels, decreasing glutamate release. Side effects include rash (rarely severe), dizziness, and insomnia.

4. Clobazam – benzodiazepine anti-seizure drug
Clobazam is a long-acting benzodiazepine used as add-on therapy for difficult-to-control seizures. It is usually given once or twice daily. The purpose is further seizure reduction when first-line drugs are not enough. Mechanistically, it enhances GABA-A receptor activity, increasing inhibitory signaling. Side effects include sedation, drooling, behavior changes, and tolerance with long-term use.

5. Methylphenidate (Ritalin, Concerta and others) – ADHD medication
Methylphenidate is a central nervous system stimulant FDA-approved for ADHD in children and adults. If a child with RNF135-related overgrowth also has ADHD, clinicians may consider it. It is taken once or several times daily depending on formulation. Mechanistically, it increases dopamine and norepinephrine in the prefrontal cortex, improving attention and reducing impulsivity. Side effects include decreased appetite, insomnia, headache, and, rarely, heart rhythm issues and misuse risk, so careful monitoring is needed.

6. Atomoxetine – non-stimulant ADHD drug
Atomoxetine is a selective norepinephrine reuptake inhibitor used for ADHD, especially when stimulants are poorly tolerated. It is taken once or twice daily. The purpose is to improve attention and reduce hyperactivity and impulsivity. Mechanistically, it increases norepinephrine in brain networks involved in executive function. Side effects can include stomach upset, sleep changes, and rare mood or liver issues.

7. Risperidone (Risperdal) – atypical antipsychotic for irritability and aggression
Risperidone is FDA-approved for irritability in autism and for certain mood and psychotic disorders. In RNF135-related overgrowth, it may be used to manage severe aggression, self-injury, or extreme irritability. It is usually given once or twice daily. Mechanistically, it blocks dopamine D2 and serotonin 5-HT2 receptors. Side effects include weight gain, metabolic changes, elevated prolactin, sedation, and movement disorders, so metabolic and movement monitoring is important.

8. Aripiprazole – atypical antipsychotic with partial agonist action
Aripiprazole is also approved for irritability in autism and mood disorders. It is sometimes preferred when weight gain with other antipsychotics is a concern. Mechanistically, it is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors, which helps stabilize dopamine signaling. Side effects include restlessness, sleep changes, and metabolic issues, although weight gain may be less than with some other drugs.

9. Selective serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine, sertraline)
SSRIs are used in children and adolescents to treat anxiety and depression, which can accompany chronic rare disorders. They are usually taken once daily. Mechanistically, SSRIs block serotonin reuptake, increasing serotonin levels in synapses. Side effects include gastrointestinal upset, headache, and, rarely, behavioral activation or suicidal thoughts in teens, so close monitoring is essential.

10. Clonidine / guanfacine – alpha-2 adrenergic agonists
These medicines are used for ADHD symptoms, tics, and sleep difficulties. They reduce sympathetic nervous system activity, which can calm hyperactivity and impulsivity. Taken once or several times daily or as extended-release, they work by stimulating alpha-2 receptors in the brainstem. Side effects include low blood pressure, dizziness, and sleepiness.

11. Recombinant human growth hormone (somatropin, Norditropin, Humatrope, Zomacton, etc.)
Growth hormone therapy is not routinely indicated for RNF135-related overgrowth and may even be inappropriate because patients are already tall. However, in rare cases with proven growth hormone deficiency, standard pediatric GH therapy may be used. These products are given as daily or less-frequent subcutaneous injections to normalize growth in GH deficiency, not to treat RNF135 itself. Side effects include joint pain, intracranial hypertension, and glucose intolerance, so endocrinologists follow strict criteria and guidelines.

12. Gonadotropin-releasing hormone (GnRH) analogs
If a child develops central precocious puberty, GnRH analogs may be used to temporarily halt puberty. They are given as injections or implants at regular intervals. Mechanistically, continuous GnRH stimulation down-regulates pituitary receptors, reducing LH and FSH and slowing sex-steroid production. Side effects can include injection-site pain and hot flushes.

13. Anti-spasticity agents (baclofen, tizanidine)
If muscle stiffness or spasticity occurs, baclofen or tizanidine may be considered. They reduce muscle tone by acting on spinal reflex circuits (baclofen on GABA-B receptors; tizanidine on alpha-2 adrenergic receptors). Side effects include drowsiness, low blood pressure, and weakness, so doses are increased slowly.

14. Melatonin
Melatonin is often used for circadian rhythm and sleep initiation problems in children with neurodevelopmental conditions. It is taken before bedtime. Mechanistically, it acts on melatonin receptors in the brain to signal “night-time” and support sleep onset. Side effects are usually mild (sleepiness, vivid dreams), but long-term effects still need more study in children.

15. Proton-pump inhibitors or H2 blockers
If reflux or feeding difficulties cause discomfort, PPIs or H2 blockers may be used to reduce stomach acid. This can make feeding more comfortable and prevent esophagitis. Side effects include diarrhea, headache, and, with long-term use, possible effects on mineral absorption.

16. Laxatives (polyethylene glycol and others)
Constipation is common in children with reduced mobility or neurological issues. Osmotic laxatives increase water in the stool to ease passage. They are used at the lowest effective dose under medical supervision. Side effects include bloating and cramps if over-dosed.

17. Vitamin D and calcium medicines (when deficient)
If blood tests show low vitamin D or poor bone mineralization, supplements or prescription strength vitamin D may be used. Mechanistically, they improve calcium absorption and bone health, which is important in tall, heavy children under orthopedic strain.

18. Antiemetics and migraine medicines (when indicated)
If migraines or frequent vomiting occur, appropriate anti-migraine or antiemetic medicines may be used following standard pediatric protocols. These act on serotonin or dopamine pathways to reduce nausea or vascular changes associated with migraine.

19. Antihistamines for allergy and sleep (short term)
Nonsedating antihistamines treat allergic symptoms. Older sedating antihistamines may sometimes be used short-term to support sleep, but only under medical guidance due to side-effect risks.

20. Emergency rescue seizure medicines (e.g., intranasal midazolam)
For children with epilepsy, families may be given a rescue medication for prolonged seizures. These benzodiazepines rapidly enhance GABA signaling to stop seizure activity, but they must be used strictly according to an emergency plan provided by the neurologist.

---

Dietary molecular supplements

These supplements are general neuro-nutritional supports, not proven cures for RNF135-related overgrowth. Always discuss with a doctor before using any supplement, especially in children.

1. Omega-3 fatty acids (DHA/EPA)
Omega-3s support brain cell membrane fluidity and anti-inflammatory signaling. They are usually provided as fish-oil or algae-oil capsules or liquids, with child-appropriate doses set by a clinician. Mechanistically, DHA is incorporated into neuronal membranes, and EPA modulates eicosanoid and resolvin pathways, which may support cognition and behavior.

2. Choline
Choline is a precursor for acetylcholine and phosphatidylcholine, vital for memory and cell membranes. Supplementation at safe doses may support cognitive development where diet is low in choline. Mechanistically, it enhances synthesis of membrane phospholipids and neurotransmitters necessary for learning and attention.

3. Vitamin D3
Vitamin D3 helps regulate calcium metabolism, immune signaling, and brain development. In children with limited sun exposure or low blood levels, clinicians may recommend drops or tablets. Mechanistically, vitamin D receptors in brain and immune cells help regulate gene expression linked to neurodevelopment and immune balance.

4. Vitamin B12
Vitamin B12 is essential for myelin formation and red blood cell production. If levels are low, oral or injectable forms can be used. Mechanistically, B12 acts as a cofactor in methylation reactions and DNA synthesis; deficiency can worsen developmental delay or neuropathy.

5. Folate (folic acid or L-methylfolate)
Folate supports DNA synthesis and methylation pathways. Supplementation is used when dietary intake is low or homocysteine is high. Mechanistically, it participates in one-carbon metabolism, important for neural tube formation and ongoing brain function.

6. Iron (when deficient)
Iron is critical for hemoglobin, energy metabolism, and dopamine signaling. Iron deficiency can mimic or worsen ADHD-like symptoms. Mechanistically, iron-dependent enzymes support neurotransmitter synthesis; correcting deficiency may improve fatigue and concentration.

7. Magnesium
Magnesium is involved in hundreds of enzymatic reactions and modulates NMDA and GABA receptors. In some children, magnesium may ease muscle cramps or mild anxiety. Mechanistically, it stabilizes neuronal membranes and helps regulate excitatory–inhibitory balance.

8. Zinc
Zinc is important for growth, immune function, and synaptic plasticity. Low zinc levels can impair appetite and immunity. Mechanistically, zinc ions modulate many enzymes and neurotransmitter receptors; balanced levels support healthy development.

9. Probiotics
Probiotic supplements aim to improve gut microbiota balance, which may indirectly affect mood, immunity, and digestion. Mechanistically, beneficial bacteria produce short-chain fatty acids, interact with gut-associated lymphoid tissue, and influence the gut–brain axis.

10. Multivitamin tailored for children with chronic conditions
A carefully selected multivitamin may prevent minor deficiencies without megadoses. Mechanistically, providing recommended intakes of multiple micronutrients supports enzyme systems across the body, particularly important where dietary variety is limited.

---

Immunity-boosting, regenerative and stem-cell–related drugs

At present, there are no approved stem-cell or gene-editing drugs specifically for RNF135-related overgrowth syndrome. The items below describe general strategies used or studied in related conditions; they remain highly specialized and must only be considered by expert teams or only within clinical trials.

1. Intravenous immunoglobulin (IVIG)
IVIG is a pooled antibody product used for certain immune deficiencies and autoimmune diseases. In very selected situations—such as coexisting immune problems—it may modulate immune responses. Mechanistically, IVIG provides a broad repertoire of antibodies and immune-modulating proteins that dampen abnormal immune activation or bridge antibody deficits.

2. Hematopoietic stem cell transplantation (HSCT)
HSCT replaces a diseased blood-forming system with donor stem cells. It is not a treatment for RNF135-related overgrowth itself, but might be used if a separate severe hematologic condition arises. Mechanistically, donor stem cells engraft and rebuild the bone marrow, providing a new immune and blood system.

3. Experimental mesenchymal stem cell (MSC) therapies
MSC therapies are being studied in various neurological and inflammatory diseases. They are not approved for RNF135-related overgrowth, but research explores whether MSCs can secrete neurotrophic and anti-inflammatory factors to support repair. Mechanistically, MSCs act mainly through paracrine signaling rather than direct tissue replacement.

4. Neurotrophic growth-factor–based approaches
Some experimental treatments aim to boost neurotrophic factors such as BDNF or GDNF to support brain plasticity. These may involve small molecules, biologics, or activity-based interventions. Mechanistically, increased neurotrophic signaling promotes synaptic growth and survival, potentially helping neural networks adapt to underlying genetic disruption.

5. mTOR/PI3K pathway-targeting drugs (research context)
Because some overgrowth syndromes involve PI3K–AKT–mTOR signaling, targeted inhibitors are being studied. For RNF135-related overgrowth, the exact pathway role is still under investigation, so such drugs remain experimental. Mechanistically, they attempt to normalize over-active growth signaling but can have significant side effects, requiring oncology-level supervision.

6. Future gene-editing or RNA-based therapies
In the longer term, technologies such as CRISPR or antisense oligonucleotides might be explored for monogenic overgrowth conditions. Mechanistically, they aim to correct, silence, or modulate the faulty gene. These approaches are still in the research stage, and any use would require rigorous clinical trials for safety and efficacy.

---

Surgical treatments

1. Orthopedic surgery for limb or spine problems
If overgrowth leads to significant limb length discrepancy, hip displacement, or severe scoliosis, orthopedic surgery may be considered. Procedures can include guided growth (epiphysiodesis), osteotomies (bone cuts), or spinal fusion. The purpose is to improve alignment, balance, and pain. Mechanistically, surgery repositions or fuses bones so mechanical forces during walking are better distributed.

2. Neurosurgical procedures for structural brain lesions
When seizures are linked to a clear, localized cortical malformation, specialized centers may consider epilepsy surgery. The purpose is to remove or disconnect seizure-generating tissue. Mechanistically, this may reduce or stop seizures, which can improve development and quality of life, but risks are significant and require exhaustive evaluation.

3. Cardiac surgery for congenital heart defects
If a child has tetralogy of Fallot or other congenital heart disease, standard pediatric cardiac surgery may be needed. The purpose is to correct abnormal blood flow and prevent heart failure or cyanosis. Mechanistically, surgeons repair septal defects, relieve outflow obstruction, or reconstruct vessels to restore more normal circulation.

4. ENT and airway surgery
Overgrowth and craniofacial features can contribute to obstructive sleep apnea or airway obstruction. Procedures such as adenotonsillectomy, airway widening, or maxillofacial corrections may improve breathing. Mechanistically, removing obstructing tissue or reshaping bones enlarges the airway lumen, reducing resistance during sleep.

5. Ophthalmologic and craniofacial procedures
If there are eyelid problems, strabismus, or skull shape issues causing visual or functional problems, ophthalmologic or craniofacial surgery might be offered. The purpose is to protect vision, brain, and cosmetic appearance. Mechanistically, these surgeries reposition bones and soft tissues to normalize eye alignment and skull shape.

---

Prevention and risk-reduction

Because RNF135-related overgrowth syndrome is genetic, it cannot be “prevented,” but many complications can be reduced:

1. Early genetic diagnosis to trigger prompt developmental and medical surveillance.

2. Regular growth, orthopedic, and neurologic follow-up to catch treatable problems early.

3. Vaccination according to national schedules to prevent severe infections that could worsen neurological or cardiac status.

4. Healthy weight management through balanced diet and activity to protect joints and heart.

5. Good sleep routines to support learning and emotional regulation.

6. Prompt treatment of seizures to limit repeated prolonged seizures and possible brain injury.

7. Regular dental and vision care to prevent avoidable pain and sensory loss.

8. Safe home environment with fall-prevention measures and supervision when needed.

9. Mental-health support to reduce anxiety and depression in both patient and caregivers.

10. Family genetic counseling to plan future pregnancies and consider options like prenatal or preimplantation genetic testing where appropriate.

---

When to see doctors

You should seek medical help urgently (emergency services) if there are:

• New or prolonged seizures, especially lasting more than a few minutes.

• Breathing difficulty, blue lips, or sudden chest pain.

• Sudden loss of consciousness, severe head injury, or repeated vomiting.

You should contact the child’s regular doctors promptly if you notice:

• Rapid change in behavior or school performance.

• New headaches, vision changes, or walking problems.

• Rapid spine curvature, hip pain, or limping.

• Possible early puberty (breast development, pubic hair, growth spurt) before age expected.

• Persistent sleep problems, loud snoring, or nighttime breathing pauses.

Regular scheduled visits with pediatric genetics, neurology, endocrinology, cardiology, rehabilitation, and primary care are essential even when the child seems well.

---

Diet: what to eat and what to avoid

1. Focus on whole foods. Offer plenty of fruits, vegetables, whole grains, and pulses to provide fiber, vitamins, and minerals for growth and gut health.

2. Adequate protein. Include eggs, fish, poultry, beans, and dairy to support muscle and bone strength, especially in a tall, heavy child.

3. Healthy fats. Use sources like fish, nuts, seeds, and plant oils to provide omega-3 and other essential fats for brain development.

4. Limit sugary drinks and snacks. High sugar intake promotes excess weight gain and dental problems, which can worsen orthopedic strain.

5. Avoid highly processed fast foods. These are often rich in salt, unhealthy fats, and calories but poor in micronutrients.

6. Maintain good hydration. Adequate water intake supports bowel function, especially if on medications that cause constipation.

7. Watch caffeine and energy drinks (for teens). These can worsen sleep, heart rhythm, and anxiety, especially with ADHD medicines.

8. Moderate portion sizes. Even in tall children, portion sizes should match energy needs to avoid obesity.

9. Consider texture adaptations. If there are feeding or swallowing difficulties, dietitians may recommend softer textures or thickened fluids.

10. Coordinate diet with medicines. Some drugs interact with grapefruit juice, high-fat meals, or require taking with food; doctors or pharmacists should advise on timing.

---

Frequently asked questions

1. Is RNF135-related overgrowth syndrome the same as Sotos syndrome?
No. Both conditions have overgrowth and learning difficulties, but they are caused by different genes (RNF135 vs NSD1) and have somewhat different facial features and associated problems. Genetic testing is needed to tell them apart.

2. How common is RNF135-related overgrowth syndrome?
It is extremely rare. Only a small number of patients with clearly documented RNF135 mutations and overgrowth have been reported in the medical literature so far, so exact frequency is unknown.

3. Is there a cure?
There is currently no cure that fixes the RNF135 genetic change. Treatment focuses on managing symptoms, supporting development, and preventing or treating complications like seizures, orthopedic problems, or heart issues.

4. Will my child’s condition get worse over time?
Growth is most rapid in childhood and adolescence and then slows. Many challenges relate to early development and learning. With appropriate support, many children can gain skills over time, although learning or behavioral differences may remain. Long-term outcomes vary because the condition is so rare.

5. Can adults with RNF135-related overgrowth live independently?
Some individuals may live semi-independently or independently with support, especially if cognitive difficulties are mild. Others may need long-term assistance. Early intervention, education support, and vocational planning improve the chance of greater independence.

6. Is the condition inherited?
RNF135-related overgrowth is usually described as an autosomal dominant condition, meaning one altered copy of the gene can cause symptoms. The variant may be inherited from an affected parent or appear “de novo” (new) in the child. Genetic counseling helps clarify this in each family.

7. Should other family members be tested?
Genetic counselors and clinical geneticists can advise which relatives might benefit from testing. Testing may be suggested for parents and siblings, especially if there are mild signs of overgrowth or learning issues.

8. Does my child have a higher risk of cancer?
Some overgrowth conditions can carry cancer risks, but the exact cancer risk for isolated RNF135-related overgrowth is not well defined yet. Current data are limited, so doctors may individualize surveillance based on personal and family history and evolving research.

9. Can physical activity make things worse?
In most cases, age-appropriate physical activity is encouraged to support muscle strength, coordination, and weight control. However, if there are joint, spine, or heart problems, activity plans should be tailored by physiotherapists and cardiologists.

10. Are vaccines safe for children with this syndrome?
Yes, standard childhood vaccines are usually recommended unless there is a specific contraindication. Vaccination helps prevent infections that could be particularly harmful in children with complex medical needs.

11. Is special schooling always necessary?
Not always. Some children may do well with extra supports in mainstream classrooms; others may benefit from specialized settings. Educational needs should be reviewed regularly and adjusted as the child grows.

12. Can diet alone treat the condition?
No diet can correct the genetic change, but healthy nutrition supports growth, brain function, and overall health. Diet is one important part of a comprehensive care plan that includes therapies and medical follow-up.

13. Should we join research studies or registries?
Participating in research or rare-disease registries can help doctors learn more about RNF135-related overgrowth and may, in the long term, support development of targeted therapies. Families should discuss risks and benefits with their care team.

14. How often should my child see specialists?
This depends on age and symptoms. Many children will need regular follow-up with genetics, neurology, endocrinology, cardiology (if heart disease is present), and rehabilitation teams at least once or twice a year, or more often when problems are active.

15. Where can I find reliable information?
Reliable information usually comes from clinical genetics clinics, peer-reviewed articles, and trusted rare-disease organizations rather than social media. Your genetics team can help identify up-to-date resources and patient support networks as more is learned about RNF135-related overgrowth syndrome.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: January 16, 2026.